Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

SciSparc Ltd. Converts Debentures into Equity, Issuing New Shares

Tipranks - Tipranks - Sat Aug 30, 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

SciSparc Ltd. ( (SPRC) ) just unveiled an update.

In August 2025, SciSparc Ltd. issued 999,528 ordinary shares to investors who converted their debentures into equity, following agreements made in February 2025. This conversion leaves $175,000 of the debentures outstanding, impacting the company’s share structure and potentially its market positioning.

More about SciSparc Ltd.

SciSparc Ltd. operates in the biotechnology industry, focusing on the development of therapies for central nervous system disorders. The company is known for its innovative approach to treating conditions such as Alzheimer’s disease and Tourette syndrome.

Average Trading Volume: 305,480

Technical Sentiment Signal: Sell

Current Market Cap: $1.62M

For detailed information about SPRC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).